A distinctive alteration of speech has been reported in patients suffering from ephedrone-induced parkinsonism. However, an objective assessment of dysarthria has not been performed in ephedrone users. We studied 28 young Caucasian men from Georgia with a previous history of ephedrone abuse and compared them to 25 age-matched healthy controls. Speech examination, brain MRI, and NNIPPS-Parkinson plus scale were performed in all patients. The accurate differential diagnosis of dysarthria subtypes was based on the quantitative acoustic analyses of 15 speech dimensions. We revealed a distinct variant of mixed dysarthria with a combination of hyperkinetic and hypokinetic components representing the altered motor programming of dystonia and bradykinesia in ephedrone-induced parkinsonism. According to acoustic analyses, all patients presented at least one affected speech dimension, whereas dysarthria was moderate in 43% and severe in 36% of patients. Further findings indicated relationships between motor subscores of dystonia and bradykinesia and speech components of loudness (r = -0.54, p < 0.01), articulation (r = 0.40, p < 0.05), and timing (r = -0.53, p < 0.01). In ephedrone-induced parkinsonism a prominent mixed hyperkinetic-hypokinetic dysarthria occurs that appears related to marked dystonia and bradykinesia and probably reflects manganese induced toxic and neurodegenerative damage to the globus pallidus internus and substantia nigra.

Department of Circuit Theory Faculty of Electrical Engineering Czech Technical University Prague Prague Czech Republic

Zobrazit více v PubMed

J Psychiatr Res. 1975 Nov;12(3):189-98 PubMed

Mov Disord. 2009 May 15;24(7):1001-8 PubMed

J Neural Transm (Vienna). 2010 May;117(5):605-12 PubMed

Neurosci Lett. 1993 Nov 12;162(1-2):192-6 PubMed

Neurology. 2000 Dec 12;55(11):1621-6 PubMed

Metab Brain Dis. 1995 Dec;10(4):259-67 PubMed

J Acoust Soc Am. 2001 May;109(5 Pt 1):2181-9 PubMed

Mov Disord. 2008 Nov 15;23(15):2224-31 PubMed

Brain Lang. 2002 Jul;82(1):65-74 PubMed

Mov Disord. 2007 Jul 15;22(9):1337-43 PubMed

Neuropsychologia. 1999 Dec;37(13):1453-60 PubMed

J Neurol Sci. 1973 Dec;20(4):415-55 PubMed

J Speech Hear Res. 1969 Jun;12(2):246-69 PubMed

Trends Neurosci. 1989 Oct;12(10):366-75 PubMed

Arch Gen Psychiatry. 1961 Jun;4:561-71 PubMed

J Acoust Soc Am. 2011 Jan;129(1):350-67 PubMed

N Engl J Med. 2008 Mar 6;358(10):1009-17 PubMed

J Neurosurg. 1997 Oct;87(4):491-8 PubMed

Parkinsons Dis. 2011 Feb 17;2011:865319 PubMed

Arch Neurol. 2005 Sep;62(9):1385-90 PubMed

J Speech Lang Hear Res. 2007 Aug;50(4):899-912 PubMed

J Neural Transm (Vienna). 2013 Feb;120(2):319-29 PubMed

PLoS One. 2011;6(8):e22293 PubMed

Zh Nevrol Psikhiatr Im S S Korsakova. 2005;105(7):12-20 PubMed

J Commun Disord. 2010 Jan-Feb;43(1):21-34 PubMed

PLoS One. 2013 Jun 10;8(6):e65881 PubMed

J Neuropathol Exp Neurol. 2007 Aug;66(8):675-82 PubMed

Neurotoxicology. 2006 May;27(3):340-6 PubMed

Computerized analysis of hypomimia and hypokinetic dysarthria for improved diagnosis of Parkinson's disease

Speech Biomarkers in Rapid Eye Movement Sleep Behavior Disorder and Parkinson Disease

Distinctive speech signature in cerebellar and parkinsonian subtypes of multiple system atrophy

Effect of pallidal deep-brain stimulation on articulation rate in dystonia

Automatic Evaluation of Speech Rhythm Instability and Acceleration in Dysarthrias Associated with Basal Ganglia Dysfunction

Speech disorders reflect differing pathophysiology in Parkinson's disease, progressive supranuclear palsy and multiple system atrophy

Phonatory dysfunction as a preclinical symptom of Huntington disease

Eye movements in ephedrone-induced parkinsonism